

Moderna buys Japanese startup OriCiro for \$85M

09 January 2023 | News

OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines



Moderna, a US-based biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and OriCiro Genomics K.K., a pioneer in cell-free DNA synthesis and amplification technologies, have entered into a definitive agreement through which Moderna will acquire OriCiro for \$85 million.

"With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing," said Stéphane Bancel, Chief Executive Officer of Moderna. "OriCiro's technology strategically complements our manufacturing expertise and further accelerates our research and development engine. We look forward to welcoming the OriCiro team to Moderna."

OriCiro Genomics, founded in December 2018, is focused on the development and commercialisation of cell-free synthesis and amplification of plasmid DNAs for applications in gene/cell-based therapies and synthetic biology. OriCiro's proprietary technologies are positioned to unlock and expedite the possibilities of advanced therapeutics and synthetic biology by providing a powerful tool to be used for research, development and manufacturing of plasmid DNA.